Modified Maimendong Decoction in the Treatment of Patients with Idiopathic Pulmonary Fibrosis: Study Protocol for a Randomized Controlled Trial

Hospital of Chengdu University of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Between the ages of 18 and 75, male and female;
•2. Diagnosis according to guidelines of the Idiopathic Pulmonary Fibrosis by ATS/ERS/JRS/ALAT in 2018;
•3. In line with the diagnostic criteria of TCM syndrome Qi and Yin deficiency;
•4. Good ability to read, understand and write research-related materials, and voluntary compliance with all testing requirements;
•5. Volunteer for a study, sign an informed consent.

•1. Patients with acute exacerbation of IPF or those with FVC% < 50% or those with obvious pulmonary infection should be treated with anti-infection therapy;
•2. Patients with chronic obstructive pulmonary disease, interstitial lung disease, active pulmonary tuberculosis, bronchiectasis and other chronic lung diseases that need intervention or treatment;
•3. Patients with severe mental and psychological disorders, cardiovascular, liver and kidney, endocrine, hematopoietic system, malignant tumor and other serious primary diseases;
•4. Patients who had taken glucocorticoid within 1 month; those who had taken immunosuppressants within 1 month; those who had taken Pirfenidone, Nintedanib or antacid within 1 month;
•5. Patients who are unwilling or unable to change the current treatment plan;
•6. Patients who are known to be allergic to the test drug or some traditional Chinese medicine in the test drug;
•7. Women in lactation, pregnancy or preparing for pregnancy;
•8. Patients who have participated in other clinical studies in recent six months.

发起方

Hospital of Chengdu University of traditional Chinese Medicine